Combining two antifungal agents does not enhance survival of Galleria mellonella larvae infected with Madurella mycetomatis

To determine whether combination therapy would improve therapeutic outcome in eumycetoma caused by Madurella mycetomatis.

[1]  Wendy Kloezen,et al.  Amphotericin B and terbinafine but not the azoles prolong survival in Galleria mellonella larvae infected with Madurella mycetomatis , 2018, Medical mycology.

[2]  C. Ramana,et al.  Fungal cell membrane—promising drug target for antifungal therapy , 2016, Journal of applied microbiology.

[3]  A. Fahal,et al.  Mycetoma: A Long Journey from Neglect , 2016, PLoS neglected tropical diseases.

[4]  S. H. Alves,et al.  Interference of melanin in the susceptibility profile of Sporothrix species to amphotericin B. , 2016, Revista iberoamericana de micologia.

[5]  A. Casadevall,et al.  Activation of Melanin Synthesis in Alternaria infectoria by Antifungal Drugs , 2015, Antimicrobial Agents and Chemotherapy.

[6]  I. Bakker-Woudenberg,et al.  Amphotericin B but not itraconazole is able to prevent grain formation in experimental Madurella mycetomatis mycetoma in mice , 2015, The British journal of dermatology.

[7]  R. Rajendran,et al.  Prior in vitro exposure to voriconazole confers resistance to amphotericin B in Aspergillus fumigatus biofilms. , 2015, International journal of antimicrobial agents.

[8]  Wendy Kloezen,et al.  A Madurella mycetomatis Grain Model in Galleria mellonella Larvae , 2015, PLoS neglected tropical diseases.

[9]  D. A. Santos,et al.  Melanin Protects Paracoccidioides brasiliensis from the Effects of Antimicrobial Photodynamic Inhibition and Antifungal Drugs , 2015, Antimicrobial Agents and Chemotherapy.

[10]  S. Rozental,et al.  Amphotericin B, alone or followed by itraconazole therapy, is effective in the control of experimental disseminated sporotrichosis by Sporothrix brasiliensis. , 2015, Medical mycology.

[11]  G. S. de Hoog,et al.  In Vitro Interaction of Currently Used Azoles with Terbinafine against Madurella mycetomatis , 2014, Antimicrobial Agents and Chemotherapy.

[12]  A. Fahal,et al.  Mycetoma Medical Therapy , 2014, PLoS neglected tropical diseases.

[13]  E. Clementi,et al.  A Histological Procedure to Study Fungal Infection in the Wax Moth Galleria Mellonella , 2014, European journal of histochemistry : EJH.

[14]  R. Gupta,et al.  Treatment of actinomycetoma foot – our experience with ten patients , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[15]  M. Develoux,et al.  Management of mycetomas in France. , 2013, Médecine et maladies infectieuses.

[16]  J. Meis,et al.  In Vitro Antifungal Activity of Isavuconazole against Madurella mycetomatis , 2012, Antimicrobial Agents and Chemotherapy.

[17]  R. Rajendran,et al.  Azole Resistance of Aspergillus fumigatus Biofilms Is Partly Associated with Efflux Pump Activity , 2011, Antimicrobial Agents and Chemotherapy.

[18]  J. Guarro,et al.  Treatment of murine Fusarium verticillioides infection with liposomal amphotericin B plus terbinafine. , 2011, International journal of antimicrobial agents.

[19]  S. Tolat,et al.  Modified Welsh regimen: a promising therapy for actinomycetoma. , 2008, Journal of drugs in dermatology : JDD.

[20]  L. Castro,et al.  Clinical and mycologic findings and therapeutic outcome of 27 mycetoma patients from São Paulo, Brazil , 2008, International journal of dermatology.

[21]  A. van Belkum,et al.  Melanin biosynthesis in Madurella mycetomatis and its effect on susceptibility to itraconazole and ketoconazole. , 2007, Microbes and infection.

[22]  Vinod K. Sharma,et al.  A modified two-step treatment for actinomycetoma. , 2007, Indian journal of dermatology, venereology and leprology.

[23]  D. Andes.  Pharmacokinetics and pharmacodynamics of antifungals. , 2006, Infectious disease clinics of North America.

[24]  D. Stevens,et al.  Efficacy of Abelcet alone, or in combination therapy, against experimental central nervous system aspergillosis. , 2006, The Journal of antimicrobial chemotherapy.

[25]  M. Dieng,et al.  Clinical efficacy and safety of oral terbinafine in fungal mycetoma , 2006, International journal of dermatology.

[26]  M. Rinaldi,et al.  Combination Therapy with Terbinafine and Amphotericin B in a Rabbit Model of Experimental Invasive Aspergillosis , 2005, Antimicrobial Agents and Chemotherapy.

[27]  A. Gupta,et al.  Alternate week and combination itraconazole and terbinafine therapy for chromoblastomycosis caused by Fonsecaea pedrosoi in Brazil. , 2002, Medical mycology.

[28]  M. Ramam,et al.  A two-step schedule for the treatment of actinomycotic mycetomas. , 2000, Acta dermato-venereologica.

[29]  L. Di Francesco,et al.  Interactions between Triazoles and Amphotericin B against Cryptococcus neoformans , 2000, Antimicrobial Agents and Chemotherapy.

[30]  L. Wheat,et al.  Amphotericin B combined with itraconazole or fluconazole for treatment of histoplasmosis. , 2000, The Journal of infectious diseases.

[31]  T. Patterson,et al.  Combination therapy in experimental invasive aspergillosis. , 1993, The Journal of infectious diseases.

[32]  O. Welsh,et al.  Amikacin alone and in combination with trimethoprim-sulfamethoxazole in the treatment of actinomycotic mycetoma. , 1987, Journal of the American Academy of Dermatology.

[33]  R. Hay,et al.  Leucocyte chemotaxis to mycetoma agents--the effect of the antifungal drugs griseofulvin and ketoconazole. , 1987, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[34]  A. Polak,et al.  Combination therapy of experimental candidiasis, cryptococcosis and aspergillosis in mice. , 1982, Chemotherapy.

[35]  E. Mahgoub.  Medical management of mycetoma. , 1976, Bulletin of the World Health Organization.